Summary

Tirzepatide is a novel, synthetic peptide that functions as a dual agonist for both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By engaging both receptors, it synergistically regulates glucose homeostasis, suppresses appetite, and improves lipid metabolism more effectively than selective GLP-1 agonists alone. It is a primary subject of research for metabolic syndrome and obesity management. For research use only—not for human consumption.

Clinical Data

Large-scale clinical trials, such as the SURPASS and SURMOUNT programs, have generated substantial data on Tirzepatide’s efficacy. In comparisons with selective GLP-1 receptor agonists, Tirzepatide demonstrated superior reductions in hemoglobin A1c and body weight. Specifically, in trials involving participants with obesity, substantial weight reductions (up to 20% or more of body weight) were observed over 72 weeks. Mechanistic studies suggest that the GIP component enhances the tolerability and efficacy of GLP-1 signaling, leading to improved beta-cell function and insulin sensitivity markers across multiple study populations.